<em>Decision-IQ</em>: A Case Study in the Management of Obesity
Decision-IQ Decision-IQ

Decision-IQ: A Case Study in the Management of Obesity


This activity was developed by Med-IQ in collaboration with Duke Health.

Med-IQ      Duke Medicine
 

Released:
10/28/19
Expires:
10/27/20

Maximum Credits:

0.25
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Decision-IQ Decision-IQ
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
10/28/19

Expires:
10/27/20

Maximum Credits:
0.25
Decision-IQ Decision-IQ
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
10/28/19
Expires:
10/27/20


Maximum Credits:
0.25


Overview:

In this brief case-based activity, meet a 42-year-old woman with class 2 obesity who was recently diagnosed with diabetes. She is referred to your office because she is interested in weight-loss strategies. As you move through this activity, you will:

  • Be directed to useful resources to help you make management decisions for this patient
  • See how your answers compare with your peers’
  • Receive insights from endocrinologist Andrea Coviello, MD, on appropriate diet and pharmacologic management for this patient

CME Information:

Faculty
Andrea D. Coviello, MD, MSE, MMCi, FACE
Associate Professor of Medicine
Division of Endocrinology, Metabolism, and Nutrition
Duke University School of Medicine
Durham, NC
 
Activity Planners
Christie Avraamides, PhD
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Learning Objectives
Upon completion, participants should be able to:

  • Develop an office-based approach to medical weight management

Target Audience
This activity is intended for endocrinologists. 

Statement of Need
Obesity affects approximately 93.3 million adults in the United States and is a major contributor to chronic disease. Losing weight can decrease the number of risk factors for obesity-related diseases, including diabetes and hypertension. Weight loss is achieved by increasing energy expenditure and reducing intake, and effective weight-loss strategies include diet and exercise. For obese individuals (BMI > 30 kg/m²) or individuals who are overweight (BMI > 27 kg/m²) and have a weight-related comorbidity (eg, type 2 diabetes, hypertension, dyslipidemia), guidelines recommend consideration of a weight-loss medication. Clinicians must understand the degree of weight loss that can be expected from diet and exercise as well as the effectiveness and safety of currently available weight-loss medications.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.
 
Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Medium/Method of Participation
This CME activity consists of a 0.25-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: October 28, 2019
Expiration Date: October 27, 2020
Estimated Time to Complete This Activity: 15 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Andrea D. Coviello, MD, MSE, MMCi, FACE
Consulting fees/advisory boards: Novo Nordisk
Fees received for promotional/non-CME activities: Novo Nordisk
Contracted research: Allergan, Inc., GenFit, Regeneron Pharmaceuticals, Inc.
 
The peer reviewers and activity planners have no financial relationships to disclose.
 
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
 
Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.

System Requirements

Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit: www.med-iq.com/privacy-statement/.
 
Copyright
© 2019 Med-IQ, Inc. and Duke University Health System

 

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.

We recently updated our Privacy Notice and Terms of Use.